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Background: Increased morbidity and mortality associated with conventional glucocorticoid replacement therapy
for primary adrenal insufficiency (primary AI; estimated prevalence 93–140/million), secondary AI (estimated
prevalence, 150–280/million, respectively) or congenital adrenal hyperplasia (estimated prevalence, approximately
65/million) may be due to the inability of typical glucocorticoid treatment regimens to reproduce the normal
circadian profile of plasma cortisol. A once-daily modified-release formulation of hydrocortisone has been
developed to provide a plasma cortisol profile that better mimics the daytime endogenous profile of cortisol.
Here, we describe the protocol for the European Adrenal Insufficiency Registry (EU-AIR), an observational study
to assess the long-term safety of modified-release hydrocortisone compared with conventional glucocorticoid
replacement therapies in routine clinical practice (ClinicalTrials.gov identifier: NCT01661387).
Methods: Patients enrolled in EU-AIR have primary or secondary AI and are receiving either modified-release or
conventional glucocorticoid replacement therapy. The primary endpoints of EU-AIR are the incidence of intercurrent
illness, adrenal crisis and serious adverse events (SAEs), as well as the duration of SAEs and dose changes related
to SAEs. Data relating to morbidity, mortality, adverse drug reactions, dosing and concomitant therapies will be
collected. Patient diaries will record illness-related dose changes between visits. All decisions concerning medical
care are made by the registry physician and patient. Enrolment is targeted at achieving 3600 patient-years of
treatment (1800 patient-years per group) for the primary analysis, which is focused on determining the non-inferiority
of once-daily modified-release replacement therapy compared with conventional glucocorticoid therapy.
Results: Recruitment began in August 2012 and, as of March 2014, 801 patients have been enrolled. Fifteen centres are
participating in Germany, the UK and Sweden, with recruitment soon to be initiated in the Netherlands.
Conclusions: EU-AIR will provide a unique opportunity not only to collect long-term safety data on a modified-release
preparation of glucocorticoid but also to evaluate baseline data on conventional glucocorticoid replacement. Such data
should help to improve the treatment of AI.Background
Adrenal insufficiency (AI) is a life-threatening disease,
characterized by signs and symptoms including weakness,
fatigue, anorexia, weight loss, nausea and vomiting [1].
Estimates for the prevalence of primary AI (Addison’s
disease) in Western Europe range from 93 to 140 per mil-
lion inhabitants, whereas the prevalence of secondary AI
(pituitary insufficiency) has been reported as 150–280 per
million inhabitants [2]. Congenital adrenal hyperplasia is* Correspondence: David.Fitts@viropharma.com
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reproduction in any medium, provided the ordue, in 95% of patients, to a defect in 21 hydroxylase in
the adrenal cortex and has a prevalence of approximately
65 per million inhabitants [3].
The aim of treatment of AI is to restore normal
physiological levels of cortisol through administration of
synthetic glucocorticoid. Conventional ‘immediate-release’
oral hydrocortisone replacement therapy has been the
mainstay of treatment for AI for more than 50 years [4],
typically given orally either two or three times daily.
Although this conventional replacement therapy extends
the life-span of patients with AI compared with untreated
patients, it results in non-physiological spikes and troughsLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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Figure 1 Flow diagram of the EU-AIR study design.
EMA, European Medicines Agency.
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compared with the general population remains reduced
[7,8], with a standardized mortality ratio of 2.7:1 reported
for Addison’s disease and from 1.73:1 to 2.17:1 for hypo-
pituitarism [9-13]. The causes behind the increased mor-
tality in AI are not fully known, but current strategies for
managing AI are increasingly recognized as inadequate
[14], with an overall frequency of 6.3 adrenal crises per
100 patient-years [15]. In addition, a recent report has
indicated that hypocortisolism during acute stress causes
deaths among adult patients with pituitary insufficiency
[16]. Conventional glucocorticoid replacement therapy
has also been associated with reduced bone mineral
density [17], depending on the dose [18], as well as
with unfavourable metabolic effects [19] and an increased
risk of cardiovascular disease [20]. Moreover, suboptimal
glucocorticoid replacement and the associated morbidities
may contribute to a poor quality of life, characterized by
negative alterations in physical activity and social, work
and family life [5,21-23].
A novel once-daily modified-release preparation of
hydrocortisone (Plenadren®, ViroPharma SPRL, Brussels,
Belgium) has recently been approved for the treatment
of AI in adults. This formulation has a dual-release
mechanism, achieved by means of an immediate-release
fraction of hydrocortisone in the outer layer of the tablet
and an extended-release fraction in the core [24]. Ad-
ministration of this modified-release preparation gener-
ates a plasma cortisol profile that mimics the natural
diurnal pattern of circulating cortisol, except for the
early morning increase in cortisol that occurs during
sleep [25]. Results of a prospective randomized trial have
shown that once-daily treatment with modified-release
hydrocortisone provides a sustained serum cortisol con-
centration for the first 4 hours after the morning dose,
followed by a steady reduction, which more closely
approximates to the physiological plasma profile than is
achieved with conventional thrice-daily dosing [6]. In
addition, 85% of all patients expressed a ‘large’ or ‘very
large’ preference for once-daily compared with thrice-
daily hydrocortisone treatment, and over 90% of patients
with diabetes mellitus expressed a preference for once-
daily treatment [6]. It is therefore reasonable to expect
that, in practice, once-daily dosing would impact positively
on compliance compared with the twice- or thrice-daily
regimens of conventional therapy.
The European Adrenal Insufficiency Registry (EU-AIR)
is a unique European, multicentre, multinational, post-
authorization, observational study established to collect
long-term data on the safety of modified-release hydrocor-
tisone and other glucocorticoid replacement therapies
used in normal clinical practice (ClinicalTrials.gov iden-
tifier: NCT01661387). The study was designed to meet a
regulatory requirement of the European Medicines Agency(EMA) for long-term safety data. The EU-AIR protocol
also provides an opportunity to analyse data beyond those
required by the EMA, including comparison of different
replacement regimens in different subgroups of patients
(e.g. those with diabetes mellitus and/or hypertension).
The present paper describes the protocol for EU-AIR, the
current status of the study and preliminary baseline data.
Methods
Study objectives
The main objective of EU-AIR is to monitor the safety
of long-term treatment with once-daily modified-release
hydrocortisone and other glucocorticoid replacement
therapies in patients with AI. The registry focuses on
intercurrent illness, adrenal crisis and serious adverse
events (SAEs). Data relating to adverse drug reactions
(ADRs) and mortality are also recorded. Safety data for
specific subgroups, including those with hypertension
and/or diabetes, hepatic or renal impairment or disor-
ders of gastrointestinal emptying or motility, as well as
pregnant or lactating women and the elderly will be
examined.
Study design
EU-AIR is an observational study in patients with primary
AI, secondary AI or congential adrenal hyperplasia who
are undergoing long-term treatment with modified-release
hydrocortisone or other glucocorticoid replacement ther-
apies. Figure 1 provides an overview of the study. Data are
collected from endocrinology centres in Germany, the
Netherlands, Sweden and the UK. All enrolled patients
will be followed during the course of routine clinical
practice for the active duration of the registry. All medical
care decisions, including those relating to treatment
choice, are entirely at the discretion of the patient and
registry physician.
The main endpoints of the study are the incidence
rates of intercurrent illness events, adrenal crisis events
and SAEs, as well as the duration of SAEs and gluco-
corticoid dose changes related to SAEs.




Informed consent √ ×
Demographic information √ ×
AI diagnosis (aetiology and year of diagnosis) √ ×
Relevant medical history √ ×
Relevant concomitant diseaseb √ √
Glucocorticoid replacement therapyc √ √
Concomitant medication √ √
Physical examinationd √ √
Vital signse √ √
Pregnancy statusf √ √
Laboratory assessmentsg √ √
DEXA √h √i
aApproximately every 6 months or more frequently in cases of complications
(e.g. adrenal crisis) or when changes to treatment are required.
bDiabetes, hypertension, other hormone deficiencies, renal/hepatic impairment
and disorders/diseases of gastrointestinal emptying/motility; year of diagnosis
to be recorded.
cGlucocorticoid replacement therapy to be specified (generic name), plus
dosing regimen and start/stop dates. Patients are defined as naive or
established on their current therapy on the basis of the threshold of < 90 days
and ≥ 90 days of treatment exposure, respectively.
dHeight (baseline only), body weight and waist circumference.
eBlood pressure (systolic and diastolic) and heart rate.
fRecorded at baseline, if available; as applicable post-baseline.
gSodium, potassium and glycated haemoglobin are recorded in the eCRF at
enrolment, if available; see Table 2 for other laboratory parameters to be
recorded during the study, as available.
hRecorded in the eCRF at baseline in patients identified as at high risk in
centres routinely performing DEXA.
iAs performed during routine clinic visits (every 2–3 years in patients identified
as at high risk).
AI, adrenal insufficiency; DEXA, dual-energy X-ray absorptiometry; eCRF, electronic
case report form.
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case report form (eCRF) at enrolment, and thereafter at
routine clinic visits (every 6–12 months). More frequent
visits to the registry physician can be made in cases of
complications (e.g. adrenal crisis) or when changes in
glucocorticoid replacement therapy are required.
The study is open ended; a decision to terminate it
would be based on mutual agreement between the study
sponsor and the Committee for Medicinal Products for
Human Use.
Study population
All patients with a diagnosis of AI at participating clinics
and who are receiving modified-release hydrocortisone
or other glucocorticoid replacement therapies are eligible
for inclusion in the study. Any patients participating in an
interventional clinical study are excluded and must wait
for 3 months after completion of the interventional study
before enrolling in EU-AIR.
All enrolled patients or their parent(s)/legal guardian(s)
are required to provide written informed consent/assent.
The study protocol has been approved by each country
in which patients are enrolled, and then cascaded down
to the individual centres. Ethical Committee approval in
the Netherlands is currently pending. In Germany, only
adult patients with AI are eligible for inclusion in the
study.
Treatments
All decisions regarding treatment and patient care are
made by the physician and/or patient. No guidance is
given on these issues in the study protocol.
Patient withdrawal
A patient may discontinue their involvement in the
registry either at their own request or if it is the opinion
of the registry physician that it is not in the patient’s best
interest to continue. Reasons for discontinuation are re-
corded on the eCRF. Patients who discontinue modified-
release hydrocortisone are encouraged to continue in
the registry unless consent has been withdrawn.
Data collection
The data recorded in the eCRF at baseline and during
subsequent routine clinic visits are listed in Table 1.
Laboratory assessments conducted at baseline and at
routine clinic visits are listed in Table 2.
Where dual-energy X-ray absorptiometry measure-
ments are made in routine clinical practice, or in pa-
tients deemed at high risk of osteoporosis, these data
will be recorded. Patients are also monitored for inter-
current illness, adrenal crisis, SAEs (any serious event
not necessarily associated with the study medication)
and ADRs (considered to be associated with the studymedication). Investigators are responsible for determin-
ing whether an intercurrent illness or adrenal crisis has
occurred, and for determining the duration of the event
and any associated change in glucocorticoid dose. Inter-
current illness is defined as any temporal illness for
which a transient significant increase in glucocorticoid
replacement dose (e.g. doubling the dose) is needed.
Non-disease conditions, including mental or physical
stress, such as vigorous exercise, which might be covered
by an extra 5 mg dose of hydrocortisone, for example,
are excluded. The definition of an adrenal crisis was
agreed with the EMA. Specifically, an adrenal crisis was
defined as an acute impairment of general health with
the need for parenteral hydrocortisone and saline infusion.
For any ADR or SAE, the registry physician is required to
evaluate and report the onset date, outcome, end date,
severity (mild, moderate, severe or life-threatening/disab-
ling), relationship to glucocorticoid replacement therapy,
actions taken, seriousness and any change in glucocorticoid
Table 2 Laboratory assessments at baseline and at
routine clinic visits (as available)
Baseline Routine
clinic visitsa
Fasting plasma glucose √ √
Fasting insulin √ √
Glycated haemoglobin A1c √ √
Serum triglycerides √ √
Cholesterol √ √
High-density lipoprotein √ √
Low-density lipoprotein √ √
Apolipoprotein B/apolipoprotein A1 √ √
Serum sodium √ √
Serum potassium √ √
Serum renin √ √
Serum osteocalcin √ √
Serum procollagen I N-terminal propeptide √ √
aApproximately every 6 months, or more frequently in cases of complications
(e.g. adrenal crisis) or when changes to treatment are required.
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rather than ADRs.
If a pregnant woman enters the study, or a female pa-
tient becomes pregnant during the study, the patient is
requested to inform the registry physician immediately.
Patients are provided with paper-based diaries at
enrolment, in which they are asked to record any health
issues that occur between clinic visits, as well as illness-
related glucocorticoid dose changes and reasons for such
dose changes. Patients are also asked to use these diaries
to record details of any medication they receive in
addition to recording their AI treatment.
Sample size
The size of the registry has been calculated to evaluate the
non-inferiority of modified-release hydrocortisone relative
to conventional hydrocortisone replacement therapy.
Assuming a rate of four events of intercurrent illness per
patient-year and specifying a non-inferiority limit of 0.2
events per patient-year (i.e. 5% of the incidence rate), an
exposure of 1800 patient-years in each treatment group
(i.e. 3600 patient-years in total) will yield 80% power to
demonstrate non-inferiority of modified-release hydrocor-
tisone relative to conventional glucocorticoid replacement
therapy. It is anticipated that this level of exposure will
have been achieved approximately 3 years after the start of
the registry. The validity of these design assumptions will
be re-assessed after 900 patient-years of exposure in each
treatment group. Power calculations employing the ob-
served incidence of events and dropout rates will be per-
formed. Timing of the principal analysis may be revised in
the light of those calculations.Statistical analysis
Results will be analysed by treatment group (i.e. modified-
release hydrocortisone versus other glucocorticoid re-
placement therapies) and in total. SAEs and ADRs will be
summarized by individual event and system organ class.
A test of the null hypothesis that modified-release
hydrocortisone is less safe than other glucocorticoid
replacement therapies for the incidence of intercurrent
illness in patients with AI will be performed when the
registry contains data for at least 1800 patient-years of
observational time in each treatment group. This test
will examine the upper limit of a 95% confidence inter-
val (CI) for the incidence rate difference in intercurrent
illness by comparison with the non-inferiority limit (i.e.
5% of the incidence rate). Non-inferiority will be demon-
strated if the upper limit of this CI is less than the non-
inferiority limit. This methodology will also be employed
to evaluate the non-inferiority of modified-release hydro-
cortisone with respect to the incidence of adrenal crisis.
For any test of non-inferiority that is deemed significant, a
subsequent test of superiority will be performed.Reporting data
Reports from the registry, incorporating data up to and
including the most recent clinic visit for each patient, will
be provided to the EMA on a regular basis.
The registry physician, study coordinator, other desig-
nated study personnel or study monitor is required to re-
port any SAE to ViroPharma Drug Safety within 24 hours
of becoming aware of the event. Registry physicians are
responsible for reporting SAEs to their respective inde-
pendent reviewing authority, institutional review board
or independent ethics committee according to local re-
porting requirements. Cases of accidental exposure, over-
dose, other medication errors and pregnancy/lactation
exposure are also required to be reported to ViroPharma
Drug Safety.Results
The cumulative number of patients in EU-AIR since
August 2012 is shown in Figure 2. Baseline demo-
graphic data available for patients enrolled by March
2014 (n = 801) are shown in Table 3 (owing to the lag
between enrolment and data entry at study sites, some
demographic data are currently incomplete). Of the 801
patients, 301 had primary AI, 454 secondary AI and 46
CAH. Mean age (±SD) at enrolment was similar for pa-
tients with primary and secondary AI (51.6 ± 15.9 years
and 54.1 ± 16.6 years, respectively) but lower for patients
with CAH (37.3 ± 13.0 years).
At enrolment, 663 patients were receiving conven-
tional hydrocortisone replacement, 62 were receiving





























































Figure 2 Cumulative numbers of patients enrolled in EU-AIR since August 2012.
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the database.
Discussion and conclusions
Randomized controlled trials (RCTs) are generally con-
sidered the gold standard for generating safety and effi-
cacy data in the assessment of pharmaceutical utility.
However, restrictive entry criteria and stringent proto-
cols can be barriers to generalizing RCT findings to
clinical practice. Although observational studies lack the
robustness of RCTs and may include uncontrolled
confounding variables [26], they can nevertheless yield
important data to complement the results from RCTs
(e.g. in the study of rare outcomes, risk factors and side
effects) and provide valuable information on long-term
outcomes in routine clinical practice [27]. As EU-AIR
plans to enrol many more patients than would be possible
in an RCT, some weaknesses of the observational study
design may be offset by the increase in information
expected from a large study population. In addition, the
constraints of rigid exclusion and inclusion criteria applied
to RCTs may limit the ability to extrapolate the re-
sults to a wider population. In contrast, EU-AIR has
no obstacles to enrolment, other than the requirementTable 3 Demographic details of patients enrolled in EU-AIR a
All AI Primary AI
Number 801 301





Male 28.5 (18.7–48.9) 26.5 (18.7–4
Female 27.7 (17.9–56.4) 26.1 (17.9–4
Values are means, with the range given in parentheses.
AI, adrenal insufficiency; BMI, body mass index; CAH, congenital adrenal hyperplasiathat participants are receiving glucocorticoid replace-
ment therapy. This feature allows, dependent on local
approval, the participation of pregnant women, children
and other patients with AI who would not qualify for
inclusion in an RCT.
EU-AIR will provide extensive outcomes data over a
longer time period than the randomized crossover trial
that preceded it [6]. The extent to which RCT data are
representative of outcomes obtained in routine clinical
practice may be particularly pertinent in the case of AI,
given the complexity of the conventional dosing regimen,
patient self-adjustment of the dose, compliance issues
with prescribed treatment regimens and the difficulties
associated with optimizing maintenance dosing [28]. It is
expected that once-daily dosing with modified-release
hydrocortisone will be associated with improved compli-
ance when compared with conventional hydrocortisone
regimens that require more frequent dosing. It may also
be possible to evaluate the relationship between treatment
compliance and clinical outcomes, which would be diffi-
cult to achieve in a conventional RCT design.
Large-scale observational studies have demonstrated
their value in enhancing understanding of other rare
conditions and treatments. The pharmacoepidemiologicals of March 2014
Secondary AI CAH
454 46
) 54.1 (12–87) 37.3 (12–71)
236 18
218 28
8.9) 29.4 (18.9–43.2) 26.7 (19.6–39.8)
3.0) 29.0 (17.9–55.6) 29.4 (18.4–56.4)
.
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base (KIMS) has been established for nearly 20 years, dur-
ing which time it has proven itself to be a valuable tool for
monitoring the use, efficacy and safety of growth hormone
(GH) treatment in adults with GH deficiency [29]. For
example, it was shown that 2 years of GH replacement
therapy reduced the risk of cardiovascular events by 50%,
and that male sex and high total cholesterol were potential
predictors of this response [30]. Similarly, the Fabry Out-
come Survey (FOS), established in 2001 as an industry-
sponsored, physician-directed registry of patients with
Fabry disease (FD), a rare lysosomal storage disorder, has
made an important contribution to the understanding of
both the disease and the patients’ real-world experience of
enzyme replacement therapy [31]. In other rare diseases,
registries have proven valuable for revealing shortcomings
of current treatment (e.g. in patients with adrenocortical
cancer [32] or primary hyperaldosteronism [33]).
In addition to the comparison of modified-release hy-
drocortisone with traditional glucocorticoid replacement
(hydrocortisone, cortisone acetate, prednisolone, dexa-
methasone), the design of EU-AIR will allow assessment
of the range of treatments employed for AI of differing
aetiologies and in specific patient subpopulations (e.g.
those with hypertension, diabetes and/or other hormone
deficiencies). The detail recorded in the patient diary is
such that data may also be classified by prescribed drug,
dose and frequency of administration. These aspects of
the comparative design of this registry allow for prede-
fined statistical analysis, thus ensuring scientific robust-
ness in the observational setting. Within EU-AIR it is
also possible to gather health economic and resource
utilization information in addition to the required safety
data. Together, these data will generate valuable insights
into the benefits of different cortisol replacement therap-
ies in routine clinical practice.
Although it does not replicate a complete 24-hour
physiological cortisol profile (notably, it does not ac-
curately mimic the early morning cortisol peak [25]),
modified-release hydrocortisone represents a signifi-
cant step towards achieving a diurnal plasma profile
more similar to the normal circadian pattern than is
possible with standard glucocorticoid replacement ther-
apy. Thus, modified-release hydrocortisone is expected to
resolve a number of the shortcomings associated with
conventional cortisol replacement therapy, which has
remained essentially unchallenged for over 50 years, des-
pite being associated with considerable unmet needs. EU-
AIR should provide an appropriate setting to assess long-
term morbidity and mortality trends in patients receiving
modified-release and other glucocorticoid therapies, inclu-
ding parameters such as compliance and quality of life
that are difficult to evaluate effectively in the setting of a
controlled trial.In summary, EU-AIR is anticipated to become a valu-
able source of information about current approaches to
treating AI as well as the long-term safety and tolerabil-
ity of both modified-release and conventional gluco-
corticoid replacement therapy. In addition to addressing
regulatory requirements, this registry will be an enduring
data source for improving the management of AI, as has
been the case with similar databases established for other
rare conditions.
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